AIOCD Challenges Proposal to Grant Drug Licenses to Agricultural Societies

The escalating tension between India’s traditional pharmaceutical retail sector and the government’s cooperative expansion strategy reached a critical juncture this week. The All India Organisation of Chemists and Druggists (AIOCD), an apex body representing over 1.2 million pharmacists, has issued a stern warning against the proposal to allow Primary Agricultural Credit Societies (PACS) to obtain retail drug licenses. This development is not merely a trade dispute but a fundamental challenge to the regulatory framework governing the distribution of medicines in India, specifically the Drugs and Cosmetics Act of 1940 and the Pharmacy Act of 1948.

At the heart of the AIOCD’s opposition is the contention that PACS lack the professional infrastructure and technical expertise required to handle pharmaceutical products. Under current Indian law, a retail drug license is contingent upon the presence of a registered pharmacist and adherence to strict storage conditions, including cold chain maintenance for sensitive vaccines and biologics. AIOCD leadership argues that PACS, which are primarily village-level credit institutions designed to provide financial services to farmers, are ill-equipped to manage the complexities of drug interactions, dosage instructions, and the prevention of antimicrobial resistance. The organization maintains that treating medicines as general commodities within a cooperative credit environment could lead to the proliferation of substandard or counterfeit drugs in rural markets.

“

By diversifying the revenue streams of over 63,000 functional PACS, the Ministry of Cooperation aims to improve the financial viability of the cooperative sector while simultaneously increasing healthcare accessibility in remote areas.

From a regulatory perspective, the government’s push to empower PACS is part of a broader mission to transform these societies into multi-purpose service centers. By diversifying the revenue streams of over 63,000 functional PACS, the Ministry of Cooperation aims to improve the financial viability of the cooperative sector while simultaneously increasing healthcare accessibility in remote areas. However, legal experts point out that bypassing the requirement for a qualified pharmacist would necessitate significant legislative amendments. AIOCD has signaled that any attempt to dilute these professional standards will be met with legal challenges, potentially reaching the High Courts or the Supreme Court on the grounds of violating the right to safe healthcare.

The market implications of this proposal are substantial. If implemented, the move would introduce tens of thousands of new competitors into the retail pharmacy space, many of whom would benefit from government-backed infrastructure and cooperative tax advantages. Traditional chemists fear this would not only lead to market saturation but also create a two-tiered regulatory system where cooperative societies are held to more lenient standards than independent pharmacies. This comes at a time when the Indian retail pharmacy sector is already under pressure from the rapid growth of e-pharmacies and large corporate chains.

Industry analysts suggest that the government may look for a middle ground, such as restricting PACS to the sale of over-the-counter (OTC) medications or expanding their role specifically within the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) framework, which focuses on generic medicines. However, the AIOCD remains firm that even generic distribution requires professional oversight. Moving forward, the Ministry of Health and Family Welfare and the Central Drugs Standard Control Organisation (CDSCO) will likely face intense lobbying from both the cooperative sector and the pharmaceutical trade. The outcome of this regulatory battle will serve as a precedent for how India balances the need for rural service penetration with the stringent safety requirements of the healthcare industry.